Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2007

View Archived Issues

PTC Therapeutics reports phase II trial data of PTC-124 for Duchenne muscular dystrophy

GenVec receives additional funding to develop novel adenovector-based HIV vaccines

Nventa reports update on phase I trial of new HspE-7 for cervical dysplasia

Two phase III studies show efficacy of asenapine in treating mania in bipolar I disorder

Preliminary PROTECT-1 results show efficacy of CCX-282-B in Crohn's disease

Barrier announces positive results from phase IIa study of pramiconazole in onychomycosis

Recent patents cover novel discoveries for the treatment of cancer

Approval obtained in Japan for additional pediatric indications for Claritin

Positive one-year results reported for fully bioabsorbable drug-eluting stent

New therapeutic agents for metabolic disorders reported in recent patents

EMEA supports use of rosiglitazone for type 2 diabetes

Recent Johns Hopkins patent imparts new nitroxyl (HNO) donors for cardiovascular disorders

Clinical trials add to evidence of adalimumab efficacy in Crohn's disease

Biogen Idec agents discussed at multiple sclerosis congress

Positive results reported for phase I FT-105 basal insulin trial

Tezampanel meets primary endpoint in phase IIb migraine trial

Xience V everolimus-eluting stent shows continued superiority to Taxus

Peregrine submits clinical protocol for new phase II bavituximab trial

Speedel discontinues SPP-200 development and focuses on SPP-301 and next-generation renin inhibitors

Tyrosinase DNA vaccines induce T-cell responses in melanoma patients

Genzyme acquires Bioenvision and gains rights to clofarabine

Orexigen's Contrave begins third phase III trial for treatment of obesity

Genzyme's Elaprase IV 6 mg launched in Japan

CHMP issues positive opinion of MabCampath in B-CLL therapy

Genzyme's Cholestagel launched in Europe

Noven receives FDA approvable letter for Stavzor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...